Treatment with epidermal growth factor receptor inhibitor erlotinib combined with cisplatin-based chemoradiation seems safe and effective for locally advanced cervical cancer, according to a study.
Adding erlotinib did not increase treatment toxicity in squamous cell carcinoma of the head and neck, but it also did not improve survival.
Pockets of resistant cancer can be treated with focused, targeted radiation while continuing chemotherapy with the targeted drugs crizotinib or erlotinib.
The plasma test VeriStrat can predict response but not survival benefit from erlotinib in patients with advanced non-small cell lung cancer (NSCLC).
Time-lapse imaging, analytical tools, and software are combined to provide a detailed picture of a single tumor cell's response to a cancer drug.
Erlotinib is a marginally cost-effective treatment for patients with advanced non-small cell lung cancer, according to the results of an economic analysis published in the Journal of the National Cancer Institute (2010;102(5):298-306).
Sign Up for Free e-newsletters
- Choice of Breast Reconstruction After Mastectomy Affects Satisfaction, Quality of Life
- Bariatric Surgery Reduced Risk of Some Cancers in Obese Patients
- Carfilzomib Benefits May Outweigh Cardiovascular Risk in Multiple Myeloma
- The Caregivers' Cancer Journey
- Genetic Link Between Depression and Breast Cancer Remains Unclear
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
- Fertility Preservation in Hodgkin's Lymphoma Patients That Undergo Targeted Molecular Therapies: An Important Step Forward From the Chemotherapy Era
- Survey of ACEP Councilors Reveals NP, PA Staffing Models, Practice Patterns Vary
- Breath Analysis May Be an Effective Diagnostic for Pancreatic Cancer
- Genetic Susceptibility to Pancreatic Cancer Linked to 6 Specific Gene Mutations
- Dinner Hour and Sleep Habits Affect Risk of Breast, Prostate Cancers
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|